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ABSTRACT: Diabetic keratopathy is one of the most common ocular complications in diabetes mellitus. Protocol for di-
abetes induction in rat model also has been established in many centers. Nonetheless, method in developing diabetic keratopa-
thy rat model has not been well covered. Streptozotocin (STZ)-induced diabetes is widely being used as animal diabetic mod-
el. The purpose of this study is to obtain an animal model of diabetic keratopathy that can be used to study the morphology, 
metabolism, and function of cornea in cases where human samples can be difficult to obtain.A single dose STZ (50 mg/kg) 
was injected intraperitoneally to control and intervention group. Plasma glucose level concentrations were tested in day 3 post 
injections. Obtained animal model of diabetic keratopathy, with significant difference of blood glucose level between interven-
tion and control group (P<0.00). Sensibility of cornea was decreased by week 14
th
 in intervention group. Epithelial defect were 
more prominent in diabetic group. Despite the differences between human and animal characteristic of diabetic keratopathy, 
the use of animal models has contributed to better understanding of this disease and to examine more effective treatment. 
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■ INTRODUCION 
The increasing number of diabetes case in Indonesia is ac-
companied by increasing complication on the eyes, which 
leads to vision loss (Wild et al. 2004). Of which, diabetic 
keratopathy is one of the most common ocular complication 
in diabetes. Diabetic keratopathy is a disease of the cornea 
characterized by impaired morphology, metabolism, and 
function of cornea. Dry eye syndrome and impaired wound 
healing in diabetic patients also leads to diabetic keratopa-
thy (Yin et al. 2011). 
Interaction of glucose and reactive oxygen species in di-
abetic patients leads to increasing extracellular osmotic 
stress. This oxidative stress affects mitochondria permeabil-
ity, activate apoptosis of caspase cells, and induce apoptosis 
of neuron and Schwann cells. Neuronal apoptosis leads to 
irreversible nerve damage (Veira-Potter et al. 2016). 
Streptozotocin (STZ)-induced diabetes is widely being 
used as animal diabetic model. Its mechanism in selective 
destruction of pancreatic B cell is effectively creating insu-
lin deficiency, hypeprglycemia, as well as polydipsia and 
polyuria state (King 2012). Two protocols used to produce 
STZ-induced diabetic rat including multiple administrations 
of low-dose STZ and administration using a single, high 
dose STZ (Ljubimov 2017). 
Protocol for induction of diabetes rat model also has been 
carried out in many centers. Nonetheless, studies and proto-
col in developing diabetic keratopathy rat model has not 
been well covered. The aim of this paper is to share our 
experience in developing rat model of diabetic keratopathy. 
■ MATERIALS AND METHODS 
Animal care: Male Sprague-Dawley rats, 3-4 months of 
age, weighing 250-350 gram were used for the studies. 
They were housed in 30x40x20 cm cage with ambient tem-
perature of 25-30
o
C, relative humidity of 80-90%, and sta-
ble light.  
Injection of STZ: Before injection, animals were tested for 
plasma glucose concentration. They were divided randomly 
into intervention and control group. A single dose STZ (50 
mg/kg) diluted with fresh citric acid solution (0.01M pH 
4.5) was injected intraperitoneally. Control group were in-
jected with citric acid buffer. After injection, animals had 
free access to food. On day 3 post-STZ injection, tail-vein 
blood sample were drawn. Animals are considered suitable 
for study when blood glucose level of STZ-injected rat is 
≥250 mg/dl. If in 3 days glucose level has not reached 250 
mg/dl, rats were given second dose of STZ. Insulin was 
given daily to prevent adverse effect of severe hyperglyce-
mia.  
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Examination of diabetic keratopathy rat models: On 10
th
 
day post-STZ injection, animals were examined using slit 
lamp bio microscope to assess cornea integrity, irregularity, 
and epithelial defect. Before examination a single drop of 
fluorescein eye drop were administered. Sensibility of cor-
nea was assessed using Cochet-Bonnet aesthesiometer. 
■  RESULTS AND DISCUSSION  
During first week post-STZ induction, average of blood 
glucose level in diabetic group was 322±26 mg/dl, 
compared to normal group 91±1 mg/dl (Figure 1). Normal 
group revealed stable concentration of blood sugar of 89-96 
mg/dL, meanwhile in intervention group using STZ-
induction, blood sugar level were 266-365 mg/dL (P<0.00). 
 
Figure 1 Comparison of blood glucose value between normal and 
diabetic group. 
Clinical examination on keratopathy eyes were conducted 
on 10
th
 and 14
th
 week post-STZ injection (Figure 2). In 
diabetic group, there was a significant decrease in cornea 
sensibility from 55.25±1.7 mm in week 10
th
 into 42.75±1.92 
mm in  week14
th
 (P=0.012). Meanwhile in control group, 
sensibility of cornea was unremarkable from 59.33±1.21 
mm in 10
th
 week into 59.17±1.21 mm in 14
th
 week.  
 
Figure 2 Comparison of cornea sensibility value between normal 
(Control) and diabetic (STZ) group. 
Cornea epithelial defect was examined using fluorescein 
and slit lamp. Corneal lesion scoring were used to classify 
degree of lesion, diabetic group showed all subjects suffered 
from dendritic ulceration in week 14
th
, while in control 
group 4 subjects had normal epithelial and 2 subjects had 
punctate ulceration. Cornea lesion was found getting worse 
in week 14
th
 compared to week 10
th
 in diabetic model.  
The significant difference of blood sugar level between 
intervention and control groups shows the success of 
diabetes induction by streptozotocin in rats. Our diabetic 
rats blood glucose level was ranging from 266-365 mg/dL, 
whereas control rats was 89-96 mg/dL (P<0.00). Significant 
difference between STZ-treatment and control group were 
the major determinant of diabetes induction success 
(Furman 2015). 
Our study revealed a significant decrease of corneal 
sensitivity from week 10
th
 compared with week 14
th
, 
suggesting potential damage of sensory neurons with 
constant hyperglycemia. Other study revealed decrease of 
corneal sensitivity in 8
th
 week (Yin et al. 2011, Bikbova et 
al. 2016). Reduced innervation was prominent in diabetic 
rats with the reduction of long nerve fibers was documented 
(Cousen  et al. 2007). Reduced innervation also 
contributing to lacrimal gland function, thus reducing tear 
protection and contributing to dry eye (Cousen et al. 2007). 
Integration of cell junction have vital role in the formation 
and maintenance of epithelial barrier of epithelia, punctate 
keratitis is observed in some diabetic patients (Yin et al. 
2011). Our study found more severe corneal lesion in 
diabetic group, including punctate and dendritic keratitis. 
■  CONCLUSION 
Diabetic keratopathy can lead to morbidity and eventually 
vision loss. Therefore, model of diabetic keratopathy have 
been developed in animals to analyze the disease. Despite 
the differences between human and animal characteristic of 
diabetic keratopathy, the use of animal models has contri-
buted to better understanding of this disease and to examine 
more effective treatment. 
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